Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma

Trial Profile

A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms AQUILA
  • Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 09 Jan 2019 Planned End Date changed from 31 Dec 2025 to 22 Dec 2025.
    • 15 Jun 2018 Planned End Date changed from 22 Dec 2025 to 31 Dec 2025.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top